摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(3-methoxyphenyl)furan-2-carbaldehyde | 55377-84-9

中文名称
——
中文别名
——
英文名称
5-(3-methoxyphenyl)furan-2-carbaldehyde
英文别名
5-(3-methoxyphenyl)-2-furaldehyde
5-(3-methoxyphenyl)furan-2-carbaldehyde化学式
CAS
55377-84-9
化学式
C12H10O3
mdl
MFCD06740257
分子量
202.21
InChiKey
UUXZIJXDUVPRBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    39.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(3-methoxyphenyl)furan-2-carbaldehydesodium hydroxidesilver nitrate 作用下, 以25%的产率得到5-(3-甲氧基苯基)-2-糠酸
    参考文献:
    名称:
    苯基呋喃IV:5-取代的苯基-2-呋喃羧酸的水溶性3-二乙氨基-2,2-(二甲基)丙基酯
    摘要:
    制备了一系列3-二乙基氨基-2,2-(二甲基)丙基5-取代的苯基-2-呋喃甲酸酯,发现它们在体外具有作为胃肠道非抗胆碱能平滑肌解痉剂的药理活性。该系列中活性更高的化合物之一包含5-(4-硝基苯基)基团。
    DOI:
    10.1002/jps.2600690135
  • 作为产物:
    描述:
    5-溴-2-呋喃甲醛3-甲氧基苯硼酸 在 [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride 、 potassium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 以53%的产率得到5-(3-methoxyphenyl)furan-2-carbaldehyde
    参考文献:
    名称:
    Gold Catalysis: Desymmetrization in the Furan-Yne Reaction
    摘要:
    通过一条以反构型产物为主要产物的路线,合成了一系列七种对称二糠基二炔。研究了金催化的单个反对映异构体和合成对映异构体的转化。反对映异构体在非对称反应中化学选择性地生成了具有糠基和 2- 氧代丙基侧链的二氢茚二醇。异对映异构体则完全转化为低聚物/聚合物。因此,在分离二氢茚二醇时,无需从产品混合物中分离出少量的异构体。
    DOI:
    10.1055/s-0029-1218800
点击查看最新优质反应信息

文献信息

  • Discovery of (5-Phenylfuran-2-yl)methanamine Derivatives as New Human Sirtuin 2 Inhibitors
    作者:Lijiao Wang、Chao Li、Wei Chen、Chen Song、Xing Zhang、Fan Yang、Chen Wang、Yuanyuan Zhang、Shan Qian、Zhouyu Wang、Lingling Yang
    DOI:10.3390/molecules24152724
    日期:——
    Human sirtuin 2 (SIRT2), a member of the sirtuin family, has been considered as a promising drug target in cancer, neurodegenerative diseases, type II diabetes, and bacterial infections. Thus, SIRT2 inhibitors have been involved in effective treatment strategies for related diseases. Using previously established fluorescence-based assays for SIRT2 activity tests, the authors screened their in-house
    人类 Sirtuin 2 (SIRT2) 是 Sirtuin 家族的一员,被认为是治疗癌症、神经退行性疾病、II 型糖尿病和细菌感染的有希望的药物靶点。因此,SIRT2抑制剂已参与相关疾病的有效治疗策略。使用先前建立的基于荧光的 SIRT2 活性测试分析,作者筛选了他们的内部数据库并确定了一种化合物,4-(5-((3-(quinolin-5-yl)ureido)methyl)furan-2-yl )苯甲酸 (20),分别在 100 μM 和 10 μM 时对 SIRT2 显示出 63 ± 5% 和 35 ± 3% 的抑制作用。对一系列合成的 (5-苯基呋喃-2-基) 甲胺衍生物进行构效关系 (SAR) 分析,鉴定出一种强效化合物 25,其 IC50 值为 2.47 μM,比 AGK2 (IC50 = 17.75 微米)。同时,25 可能具有更好的水溶性(cLogP = 1.63 和 cLogS
  • [EN] FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE FURANCARBONYLGUANIDINE, LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:KOREA RES INST CHEM TECH
    公开号:WO2005063727A1
    公开(公告)日:2005-07-14
    The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/ reperfusion and decreases myocardial infarction rate, indicating that they have protective effect on myocardial cells. Thus, furancarbonylguanidine derivatives of the present invention can be ef­fectively used for the prevention and the treatment of ischemic heart diseases such as myocardial infarction, arrhythmia, angina pectoris, etc, and also a promising candidate for a heart protecting agent applied to reperfusion therapy including thrombolytics or cardiac surgery including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, etc.
    本发明涉及呋喃羰基胍衍生物,其制备方法以及包含这些衍生物的药物组合物。本发明的呋喃羰基胍衍生物抑制NHE-1(钠氢交换体异构体1),有助于恢复因缺血/再灌注而受损的心脏功能,降低心肌梗死率,表明它们对心肌细胞具有保护作用。因此,本发明的呋喃羰基胍衍生物可以有效用于预防和治疗心肌梗死、心律失常、心绞痛等缺血性心脏疾病,并且是应用于再灌注疗法(包括溶栓疗法或心脏手术,如冠状动脉旁路移植术、经皮冠状动脉成形术等)的心脏保护剂的有前景的候选药物。
  • Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization
    作者:Xiangqian Kong、Jie Qin、Zeng Li、Adina Vultur、Linjiang Tong、Enguang Feng、Geena Rajan、Shien Liu、Junyan Lu、Zhongjie Liang、Mingyue Zheng、Weiliang Zhu、Hualiang Jiang、Meenhard Herlyn、Hong Liu、Ronen Marmorstein、Cheng Luo
    DOI:10.1039/c2ob26081f
    日期:——
    Oncogenic mutations in critical nodes of cellular signaling pathways have been associated with tumorigenesis and progression. The B-Raf protein kinase, a key hub in the canonical MAPK signaling cascade, is mutated in a broad range of human cancers and especially in malignant melanoma. The most prevalent B-RafV600E mutant exhibits elevated kinase activity and results in constitutive activation of the MAPK pathway, thus making it a promising drug target for cancer therapy. Herein, we describe the development of novel B-RafV600E selective inhibitors via multi-step virtual screening and hierarchical hit optimization. Nine hit compounds with low micromolar IC50 values were identified as B-RafV600E inhibitors through virtual screening. Subsequent scaffold-based analogue searching and medicinal chemistry efforts significantly improved both the inhibitor potency and oncogene selectivity. In particular, compounds 22f and 22q possess nanomolar IC50 values with selectivity for B-RafV600Ein vitro and exclusive cytotoxicity against B-RafV600E harboring cancer cells.
    细胞信号通路关键节点的致癌突变与肿瘤的发生和发展有关。B-Raf蛋白激酶是典型MAPK信号级联的关键枢纽,在多种人类癌症,尤其是恶性黑色素瘤中发生突变。最常见的B-RafV600E突变体表现出较高的激酶活性,导致MAPK通路的组成性激活,从而使其成为一种很有希望的癌症治疗药物靶点。在此,我们介绍了通过多步虚拟筛选和分层命中优化开发新型 B-RafV600E 选择性抑制剂的情况。通过虚拟筛选,我们确定了九种具有低微摩尔 IC50 值的命中化合物作为 B-RafV600E 抑制剂。随后的基于支架的类似物搜索和药物化学工作显著提高了抑制剂的效力和对癌基因的选择性。其中,22f 和 22q 化合物的 IC50 值达到纳摩尔级,在体外对 B-RafV600E 具有选择性,对携带 B-RafV600E 的癌细胞具有独特的细胞毒性。
  • Mono- and Biscouplings Using Triarylbismuths for the Atom-Efficient Arylations of Functionalized Furans under Palladium Catalysis
    作者:Maddali Rao、Dheeraj Awasthi、Jalindar Talode
    DOI:10.1055/s-0032-1316567
    日期:2012.8
    Palladium-catalyzed cross-coupling reactions of functionalized bromofurans with triarylbismuths have been described for the atom-economic synthesis of functionalized arylfuran systems. The coupling reactions using triarylbismuths with various 2-bromofurans and 2,5-dibromofuran underwent smoothly to afford the corresponding 2-arylfurans and 2,5-diarylfurans in high yields in a short reaction time (one
    钯催化的功能化溴呋喃与三芳基铋的交叉偶联反应已被描述用于功能化芳基呋喃系统的原子经济合成。使用三芳基铋与各种 2-溴呋喃和 2,5-二溴呋喃的偶联反应顺利进行,在短反应时间(1 小时)内以高产率得到相应的 2-芳基呋喃和 2,5-二芳基呋喃。
  • Gold Catalysis: Desymmetrization in the Furan-Yne Reaction
    作者:A. Hashmi、Michael Wölfle、Filiz Ata、Wolfgang Frey、Frank Rominger
    DOI:10.1055/s-0029-1218800
    日期:2010.7
    A series of seven symmetric difuryl-diynes were synthesized by a route delivering an anti-configurated product as the major product. The gold-catalyzed conversion of the individual anti- and syn-diastereomers was investigated. The anti-diastereomer in a desymmetrization reaction chemoselectively delivered dihydro­indenediols with a furyl and a 2-oxopropyl side chain. The syn-dia­stereomer was completely converted into oligomeric/polymeric material. Thus, it was not necessary to separate the minor amount of the syn-diastereomers from the product mixtures in order to isolate the dihydroindenediols.
    通过一条以反构型产物为主要产物的路线,合成了一系列七种对称二糠基二炔。研究了金催化的单个反对映异构体和合成对映异构体的转化。反对映异构体在非对称反应中化学选择性地生成了具有糠基和 2- 氧代丙基侧链的二氢茚二醇。异对映异构体则完全转化为低聚物/聚合物。因此,在分离二氢茚二醇时,无需从产品混合物中分离出少量的异构体。
查看更多